<jats:p>Anifrolumab is a fully human IgG1 monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor and inhibits the signaling of all type I IFNs. Anifrolumab is indicated as an add-on therapy for adult patients with moderate to severe systemic lupus erythematosus (SLE) who do not respond to standard treatment. The authors report two patients with SLE successfully treated with anifrolumab and review its role in the immunosuppresive therapy for the disease.</jats:p>